Milestone Pharmaceuticals Inc
MIST2.070USD
-0.080-3.72%
收盤 12/22, 16:00（美東）報價延遲15分鐘
176.30M總市值
虧損本益比TTM
關於 Milestone Pharmaceuticals Inc 公司
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.
Milestone Pharmaceuticals Inc簡介
公司代碼MIST
公司名稱Milestone Pharmaceuticals Inc
上市日期May 09, 2019
CEOOliveto (Joseph)
員工數量33
證券類型Ordinary Share
年結日May 09
公司地址420-1111 boul. Dr.-Frederik-Philips
城市MONTREAL
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Canada
郵編H4M 2X6
電話15143360444
網址https://www.milestonepharma.com
公司代碼MIST
上市日期May 09, 2019
CEOOliveto (Joseph)
Milestone Pharmaceuticals Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. David Bharucha
Dr. David Bharucha
Chief Medical Officer
Chief Medical Officer
78.45K
+212.30%
Mr. Amit Hasija
Mr. Amit Hasija
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
69.20K
+260.35%
Dr. Robert James Wills, Ph.D.
Dr. Robert James Wills, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
65.00K
+333.33%
Mr. Michael John Tomsicek
Mr. Michael John Tomsicek
Independent Director
Independent Director
15.00K
--
Mr. Stuart Duty
Mr. Stuart Duty
Independent Director
Independent Director
--
--
Mr. Joeseph C. Papa
Mr. Joeseph C. Papa
Independent Director
Independent Director
--
--
Mr. Andrew Saik
Mr. Andrew Saik
Independent Director
Independent Director
--
--
Ms. Lisa M. Giles
Ms. Lisa M. Giles
Independent Director
Independent Director
--
--
Mr. Joseph Oliveto
Mr. Joseph Oliveto
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Lorenz Muller
Mr. Lorenz Muller
Chief Commercial Officer
Chief Commercial Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. David Bharucha
Dr. David Bharucha
Chief Medical Officer
Chief Medical Officer
78.45K
+212.30%
Mr. Amit Hasija
Mr. Amit Hasija
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
69.20K
+260.35%
Dr. Robert James Wills, Ph.D.
Dr. Robert James Wills, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
65.00K
+333.33%
Mr. Michael John Tomsicek
Mr. Michael John Tomsicek
Independent Director
Independent Director
15.00K
--
Mr. Stuart Duty
Mr. Stuart Duty
Independent Director
Independent Director
--
--
Mr. Joeseph C. Papa
Mr. Joeseph C. Papa
Independent Director
Independent Director
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 11月17日 週一
更新時間: 11月17日 週一
持股股東
股東類型
持股股東
持股股東
佔比
Simplify Asset Management Inc
9.34%
Adage Capital Management, L.P.
8.19%
Trails Edge Capital Partners LP
4.50%
OrbiMed Advisors, LLC
3.78%
Morgan Stanley & Co. LLC
3.09%
其他
71.09%
持股股東
持股股東
佔比
Simplify Asset Management Inc
9.34%
Adage Capital Management, L.P.
8.19%
Trails Edge Capital Partners LP
4.50%
OrbiMed Advisors, LLC
3.78%
Morgan Stanley & Co. LLC
3.09%
其他
71.09%
股東類型
持股股東
佔比
Investment Advisor
16.23%
Hedge Fund
14.25%
Research Firm
5.04%
Investment Advisor/Hedge Fund
3.94%
Private Equity
3.78%
Individual Investor
3.57%
Venture Capital
1.22%
Family Office
1.17%
Bank and Trust
0.02%
其他
50.77%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
99
19.38M
22.80%
-5.64M
2025Q2
99
14.54M
18.86%
-15.65M
2025Q1
102
12.26M
22.94%
-17.24M
2024Q4
99
25.17M
47.19%
-9.38M
2024Q3
113
29.31M
55.02%
-13.44M
2024Q2
115
30.81M
57.87%
-11.80M
2024Q1
116
31.96M
60.43%
+3.19M
2023Q4
112
18.49M
55.02%
-13.59M
2023Q3
109
20.24M
60.32%
-12.06M
2023Q2
108
21.35M
63.87%
-11.78M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Simplify Asset Management Inc
990.00K
1.16%
+140.00K
+16.47%
Jun 30, 2025
Trails Edge Capital Partners LP
5.33M
6.27%
+5.33M
--
Jul 14, 2025
Morgan Stanley & Co. LLC
817.82K
0.96%
-148.10K
-15.33%
Jun 30, 2025
Oliveto (Joseph Gerard)
2.51M
2.95%
+66.67K
+2.73%
Jul 11, 2025
RTW Investments L.P.
2.51M
2.95%
--
--
Jun 30, 2025
Propel Bio Management, LLC
1.79M
2.11%
+340.00K
+23.42%
Jun 30, 2025
查看更多
持股ETF
更新時間: 12月2日 週二
更新時間: 12月2日 週二
機構名稱
佔比
Simplify Propel Opportunities ETF
8.04%
SPDR S&P International Small Cap ETF
0.01%
Avantis US Small Cap Equity ETF
0%
Simplify Propel Opportunities ETF
佔比8.04%
SPDR S&P International Small Cap ETF
佔比0.01%
Avantis US Small Cap Equity ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
常見問題
Milestone Pharmaceuticals Inc的前五大股東是誰？
Milestone Pharmaceuticals Inc的前五大股東如下：
Simplify Asset Management Inc持有股份：990.00K佔總股份比例：1.16%。
Trails Edge Capital Partners LP持有股份：5.33M佔總股份比例：6.27%。
Morgan Stanley & Co. LLC持有股份：817.82K佔總股份比例：0.96%。
Oliveto (Joseph Gerard)持有股份：2.51M佔總股份比例：2.95%。
RTW Investments L.P.持有股份：2.51M佔總股份比例：2.95%。
Simplify Asset Management Inc持有股份：990.00K佔總股份比例：1.16%。
Trails Edge Capital Partners LP持有股份：5.33M佔總股份比例：6.27%。
Morgan Stanley & Co. LLC持有股份：817.82K佔總股份比例：0.96%。
Oliveto (Joseph Gerard)持有股份：2.51M佔總股份比例：2.95%。
RTW Investments L.P.持有股份：2.51M佔總股份比例：2.95%。
Milestone Pharmaceuticals Inc的前三大股東類型是什麼？
Milestone Pharmaceuticals Inc 的前三大股東類型分別是：
Simplify Asset Management Inc
Adage Capital Management, L.P.
Trails Edge Capital Partners LP
Simplify Asset Management Inc
Adage Capital Management, L.P.
Trails Edge Capital Partners LP
有多少機構持有Milestone Pharmaceuticals Inc(MIST)的股份？
截至2025Q3，共有99家機構持有Milestone Pharmaceuticals Inc的股份，合計持有的股份價值約為19.38M，占公司總股份的22.80% 。與2025Q2相比，機構持股有所增加，增幅為3.94%。
哪個業務部門對Milestone Pharmaceuticals Inc的收入貢獻最大？
在--，--業務部門對Milestone Pharmaceuticals Inc的收入貢獻最大，創收--，占總收入的--% 。
